Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 21,498	$ 26,537
Available-for-sale securities	57,714	36,698
Interest receivable	387	140
Convertible note receivable, related party	1,921
Accounts receivable, net of allowance for doubtful accounts of $245 and $197 at July 31, 2023 and July 31, 2022, respectively	213	157
Prepaid expenses and other current assets	914	4,621
Assets held-for-sale		40,194
Investment in equity securities	294
Total current assets	82,941	108,347
Property and equipment, net	1,695	1,770
In-process research and development and patents	1,575	1,575
Other assets	9	1,387
TOTAL ASSETS	98,829	118,320
CURRENT LIABILITIES
Accounts payable	333	564
Accrued expenses	763	1,875
Other current liabilities	1,023	3,518
Note payable, net of debt issuance costs, held-for-sale		15,000
Total current liabilities	2,145	21,026
Other liabilities	55	88
TOTAL LIABILITIES	2,200	21,114
COMMITMENTS AND CONTINGENCIES
EQUITY
Additional paid-in capital	264,010	262,023
Accumulated deficit	(167,333)	(165,457)
Accumulated other comprehensive loss related to unrealized loss on available-for-sale securities	(353)	(63)
Accumulated other comprehensive income related to foreign currency translation adjustment	3,725	3,767
Total equity attributable to Rafael Holdings, Inc.	100,293	100,515
Noncontrolling interests	(3,664)	(3,309)
TOTAL EQUITY	96,629	97,206
TOTAL LIABILITIES AND EQUITY	98,829	118,320
Class A Common Stock
EQUITY
Common stock value	8	8
Class B Common Stock
EQUITY
Common stock value	236	237
Other Pharmaceuticals
CURRENT ASSETS
Investments	65	477
Hedge Funds
CURRENT ASSETS
Investments	4,984	4,764
Day Three Labs Inc
CURRENT ASSETS
Investments	2,797
Cyclo Therapeutics Inc
CURRENT ASSETS
Investments	4,763
Related Party
CURRENT LIABILITIES
Other current liabilities	$ 26	$ 69